Major Quality Standards for Medicines in India

Medicines in India are regulated through statutory controls, manufacturing and testing practices, and official quality standards. Together, these measures govern the production, import and sale of drugs, support compliance monitoring, and help protect consumers by promoting the availability of safe, effective and quality-assured products.

Legal Framework: Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act, 1940 is the principal legislation governing the import, manufacture, distribution and sale of drugs and cosmetics in India. It establishes the framework for regulatory authorities and quality controls, with the aim of safeguarding the safety, efficacy and quality of products.

• Prohibited products: The Act bans the manufacture, distribution and sale of adulterated, misbranded or substandard drugs and cosmetics.
• Licensing: Licences are required for manufacturing and selling drugs and cosmetics.
• Detailed rules: The Drugs Rules, 1945, made under the Act, set out provisions on matters including drug classification, storage, sale and prescription.

Schedule M of the Drugs and Cosmetics Rules, 1945, specifies Good Manufacturing Practices (GMP). The Act and Rules together provide the legal basis for quality control across regulated pharmaceutical activities.

Central Drugs Standard Control Organisation

The Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health and Family Welfare, is India’s apex regulatory body for pharmaceuticals, medical devices and clinical trials. It is headed by the Drugs Controller General of India (DCGI).

• Central responsibilities: CDSCO regulates imported drugs, approves new drugs and clinical trials, sets drug standards and enforces the Drugs and Cosmetics Act.
• Centre–State coordination: It coordinates with State Drug Control Organisations, which handle licensing and monitoring at the state level.
• Infrastructure: CDSCO operates six zonal offices, four sub-zonal offices, 13 port offices and seven laboratories.

Quality assurance depends on both regulatory standards and their implementation. Licensing, monitoring and enforcement help translate statutory requirements into controls over the products entering the market and the activities of regulated entities.

Good Practices and Quality Systems

Good practices set defined requirements for the production of medicines, the reliability of non-clinical study data and the ethical conduct of clinical trials. Their scopes differ, but each supports quality assurance and consumer health protection.

Good Manufacturing Practices

GMP aims to ensure pharmaceutical products are consistently produced and controlled according to quality standards. Schedule M covers production conditions and quality systems, including premises, plant and equipment, personnel hygiene and operational controls. The Revised Schedule M, updated in 2023, aligns Indian manufacturing requirements with global WHO-GMP principles. Its emphasis includes product quality, patient safety and data integrity. Compliance with these requirements is central to controlling the manufacturing process and maintaining consistent product quality.

Good Laboratory Practices

GLP is a quality system for non-clinical health and environmental safety studies. It supports the reliability and scientific integrity of study data through structured workflows, documentation and archiving. GLP became mandatory in India through a 2010 amendment to the Drugs and Cosmetics Rules. The National GLP Compliance Monitoring Authority (NGCMA) oversees GLP certification.

Good Clinical Practices

GCP provides ethical and scientific quality standards for designing, conducting, recording and reporting clinical trials involving human subjects. Its central concerns include protecting participants’ rights and ensuring the authenticity of biomedical data. CDSCO has formulated GCP guidelines for clinical trials in India based on international standards.

Indian Pharmacopoeia Commission

The Indian Pharmacopoeia Commission (IPC) is an autonomous institution under the Ministry of Health and Family Welfare. It publishes the Indian Pharmacopoeia (IP), the official compendium of drug quality standards for products manufactured, imported and sold in India.

• Monographs: IP monographs specify the identity, purity and strength of drug substances, excipients and finished dosage forms.
• Mandatory standards: Pharmaceutical manufacturers must comply with the applicable IP standards.
• Rational use: IPC also publishes the National Formulary of India (NFI) to promote the rational use of generic medicines.

Import Rules and Shelf-Life Requirements

Rule 31 of the Drugs Rules, 1945, governs drug imports. The Drugs (Thirteenth Amendment) Rules, 2026, issued by the Ministry of Health and Family Welfare, changed the residual shelf-life test applied by Indian licensing authorities.

• Most imported drugs: Import cannot be permitted if less than 12 months of residual shelf life remains on the date of import.
• Earlier requirement: The amendment replaced the earlier condition that more than 60% of the drug’s approved shelf life must remain.
• Separate threshold: Biological drugs and radiopharmaceuticals may be imported when at least 60% of their labelled shelf life remains.
• Consultation: Draft changes were published for public consultation on June 22, 2026. The final amendment followed consultation with the Drugs Technical Advisory Board (DTAB) and public feedback.

The revised thresholds seek to ease imports, simplify regulation, improve supply-chain efficiency and reduce wastage while ensuring medicines have adequate usable shelf life. The requirements make residual shelf life a specific compliance consideration for import licensing.

Key Prelims Takeaways

• Legal basis: The Drugs and Cosmetics Act, 1940, and Drugs Rules, 1945, underpin drug quality regulation.
• Regulator: CDSCO is headed by the DCGI; state organisations handle state-level licensing and monitoring.
• Manufacturing: Schedule M sets GMP requirements; its 2023 revision aligns with WHO-GMP principles.
• Study standards: GLP applies to non-clinical studies, while GCP governs ethical and scientific standards for clinical trials.
• Official standards: IPC publishes the Indian Pharmacopoeia, whose applicable standards are mandatory for manufacturers.
• Imports: The 2026 amendment sets a 12-month residual shelf-life threshold for most drugs and a 60% labelled-life threshold for biological drugs and radiopharmaceuticals.

Recent Context

The Drugs (Thirteenth Amendment) Rules, 2026, came into force on October 28, 2026, amending Rule 31 of the Drugs Rules, 1945. The revised shelf-life thresholds change import licensing requirements while aiming to improve supply-chain efficiency and limit wastage.